X0206 3 2015-10-07 0 0001501989 CytomX Therapeutics, Inc. CTMX 0001538676 Canaan IX L.P. 285 RIVERSIDE AVENUE, SUITE 250 WESTPORT CT 06880 1 0 1 0 0001654586 Canaan Partners IX LLC 285 RIVERSIDE AVENUE, SUITE 250 WESTPORT CT 06880 1 0 1 0 Series B-1 Redeemable Convertible Preferred Stock Common Stock 3566337 I See Footnote Series C Redeemable Convertible Preferred Stock Common Stock 1318418 I See Footnote Each share of the issuer's Series B-1 convertible preferred stock will automatically convert into one (1) share of the issuer's Common Stock immediately prior to the completion of the issuer's initial public offering ("IPO"), for no additional consideration, and has no expiration date. The shares are held directly by Canaan IX L.P. (the "Canaan Fund"). The sole general partner of the Canaan Fund is Canaan Partners IX LLC ("Canaan IX", and together with the Canaan Fund, the "Canaan Entities"), and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. Timothy Shannon, a non-managing member of Canaan IX, serves as representative of the Canaan Entities on the issuer's board of directors. Canaan IX disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any. Each share of the issuer's Series C convertible preferred stock will automatically convert into one (1) share of the issuer's Common Stock immediately prior to the completion of the issuer's IPO, for no additional consideration, and has no expiration date. Exhibit 24 Power of Attorney and Exhibit 99 Joint Filer Information Canaan IX L.P., By: Canaan Partners IXLLC, its general partner, By: /s/ Jaime Slocum, Attorney-in-Fact 2015-10-07 Canaan Partners IX LLC, By: /s/ Jaime Slocum, Attorney-in-Fact 2015-10-07